Effects of Akkermansia Muciniphila-Based Probiotics on Autonomic and Vascular Function
Effects of Akkermansia Muciniphila-Based Probiotics on Autonomic and Vascular Function in Humans
This randomized, double-blind, placebo-controlled pilot study will investigate the effects of an Akkermansia muciniphila-based probiotic supplement, Panthea Core, on autonomic and vascular function in postmenopausal women with hypertension.
Up to 60 participants aged 45 to 65 years will be enrolled to obtain approximately 40 evaluable datasets. Participants will be randomly assigned to receive Panthea Core or a matched placebo capsule daily for 12 weeks.
The study will evaluate safety, tolerability, menopausal symptoms, and changes in autonomic and vascular physiology. The primary mechanistic outcome is muscle sympathetic nerve activity (MSNA), measured using microneurography. Secondary physiological outcomes include heart rate variability, baroreflex sensitivity, endothelial function assessed by flow-mediated dilation, and blood pressure.
Additional assessments will include sleep, menopausal symptoms, mood, cognitive function, circulating metabolic markers, and gut microbiome composition. Participants will complete baseline and post-intervention assessments, with additional safety monitoring throughout supplementation and approximately one month after the intervention.
Visão geral do estudo
Status
Status
Condições
Condições
Intervenção / Tratamento
Intervenção / Tratamento
Descrição detalhada
Akkermansia muciniphila is a bacterium normally found in the human gastrointestinal tract that has been associated with metabolic and immune regulation. Previous research suggests that changes in Akkermansia muciniphila abundance may be related to blood pressure regulation, autonomic nervous system function, and vascular health. However, the effects of direct supplementation on human autonomic and endothelial physiology have not been adequately characterized.
This pilot study will evaluate the effects of a 12-week Akkermansia muciniphila-based probiotic supplement, Panthea Core, in postmenopausal women with hypertension. Hypertension is used as a physiological model of autonomic and vascular dysregulation, rather than as a treatment endpoint.
Participants will be randomized to Panthea Core or matched placebo in a double-blind, parallel-group design. The study plans to recruit up to 60 participants to obtain approximately 40 evaluable datasets.
Participants will complete three in-person study visits, including informed consent and two physiological assessment visits. During the baseline and post-intervention assessments, autonomic nervous system activity will be evaluated using microneurography to measure muscle sympathetic nerve activity, electrocardiography to assess heart rate variability, and physiological testing to assess baroreflex sensitivity.
Vascular endothelial function will be assessed using brachial artery flow-mediated dilation. Blood pressure and heart rate will also be measured.
Additional evaluations include laboratory safety measurements, metabolic and hormonal biomarkers, menopausal symptoms, sleep quality, mood, cognition, anthropometric measurements, dietary intake, and stool-based microbiome profiling.
Participants will take their assigned supplement or placebo daily for 12 weeks. Adverse events and gastrointestinal tolerability will be assessed through biweekly questionnaires and participant-initiated reporting. A follow-up contact approximately one month after the final testing visit will assess additional symptoms and adverse events.
The study is intended to generate preliminary mechanistic, safety, and tolerability data to inform the design of subsequent clinical research. As a pilot study, it is not powered to establish definitive treatment efficacy.
Tipo de estudo
Tipo de estudo
Inscrição (Estimado)
Inscrição
Estágio
Estágio
- Não aplicável
Contactos e Locais
Contato de estudo
Contato de estudo
- Nome: Manda Keller-Ross
- Número de telefone: 612-625-3175
- E-mail: kell0529@umn.edu
Estude backup de contato
- Nome: Emma Lee
- Número de telefone: 612-301-8617
- E-mail: leex4357@umn.edu
Locais de estudo
-
-
Minnesota
-
Minneapolis, Minnesota, Estados Unidos, 55455
- University of Minnesota - Children's Rehabilitation Center
-
Contato:
- Manda Keller-Ross
- Número de telefone: 612-625-3175
- E-mail: kell0529@umn.edu
-
Contato:
- Emma Lee
- E-mail: leex4357@umn.edu
-
-
Critérios de participação
Critérios de elegibilidade
Critérios de elegibilidade
Idades elegíveis para estudo
Aceita Voluntários Saudáveis
Gêneros Elegíveis para o Estudo
Descrição
Inclusion Criteria:
- Female individuals, assigned female sex at birth, aged 45 to 65 years.
- Clinician-diagnosed hypertension, either controlled or uncontrolled.
- Postmenopausal status, defined as at least 12 months without menstruation or prior surgical removal of the ovaries.
- Willing and able to provide informed consent.
Exclusion Criteria:
- Nicotine/tobacco, probiotic, or antibiotic use within the previous six months.
- Body mass index of 40 kg/m² or greater.
- Use of hormonal contraceptives or systemic exogenous hormones.
- Diagnosis of diabetes.
- Respiratory disease other than well-controlled asthma.
- Severe neurological conditions, including traumatic brain injury or stroke.
- Existing endocrine abnormalities.
- History of chemotherapy.
- Surgery within the preceding six months.
- Autoimmune disorders.
- History of organ transplantation.
- Digestive disorders, including active or unstable gastrointestinal disease, major gastrointestinal surgery, or motility disorders.
- Immunosuppressive or glucocorticoid therapy.
- Chronic illnesses that preclude participation at the investigator's discretion.
- Intermittent fasting with unwillingness or inability to complete a four-week washout period before enrollment.
- Inability to speak, read, or understand English.
- Inability to provide informed consent.
Plano de estudo
Como o estudo é projetado?
Detalhes do projeto
- Finalidade Principal: Ciência básica
- Alocação: Randomizado
- Modelo Intervencional: Atribuição Paralela
- Mascaramento: Dobro
Número de braços
Armas e Intervenções
Grupo de Participantes / BraçoGrupo de Participantes / Braço |
Intervenção / TratamentoIntervenção / Tratamento |
|---|---|
|
Experimental: Panthea Core Supplementation
Participants randomized to this group will receive one daily oral capsule of Panthea Core containing live Akkermansia muciniphila and additional dietary supplement ingredients for 12 weeks. Participants will undergo baseline and post-intervention assessments of autonomic and vascular function, safety, and related physiological outcomes. |
Panthea Core is an oral probiotic formulation containing live Akkermansia muciniphila (approximately 1 × 10^8 active fluorescence units), pyridoxal-5'-phosphate (10 mg), spermidine trihydrochloride (1.2 mg), and 3,3'-diindolylmethane (100 mg). Participants will take the formulation once daily for 12 weeks. Study product will be distributed through the Investigational Drug Services Pharmacy.
Outros nomes:
|
|
Comparador de Placebo: Placebo
Participants randomized to this group will receive a matched placebo capsule daily for 12 weeks. Participants will undergo the same baseline and post-intervention assessments as those assigned to Panthea Core. |
Participants will receive a matched oral placebo capsule administered once daily for 12 weeks. The placebo will be supplied by Panthea Inc. and dispensed through the Investigational Drug Services Pharmacy.
Outros nomes:
|
O que o estudo está medindo?
Medidas de resultados primários
Medidas de resultados primários
Medida de resultado |
Descrição da medida |
Prazo |
|---|---|---|
|
Change in Muscle Sympathetic Nerve Activity (MSNA)
Prazo: Baseline to 12 weeks
|
Muscle sympathetic nerve activity will be measured using microneurography of the fibular nerve. MSNA burst frequency, expressed as bursts per minute, will be assessed at baseline and after 12 weeks of Panthea Core or placebo supplementation. Changes in MSNA will be compared between treatment groups. |
Baseline to 12 weeks
|
|
Incidence of Adverse Events
Prazo: From initiation of supplementation through approximately 4 weeks after the 12-week intervention
|
Adverse events and serious adverse events will be monitored throughout the intervention through biweekly REDCap questionnaires, participant-initiated reports, and post-intervention follow-up. The incidence and nature of adverse events will be summarized by treatment group to evaluate the safety and tolerability of Panthea Core. |
From initiation of supplementation through approximately 4 weeks after the 12-week intervention
|
|
Change in Comprehensive Metabolic Panel Laboratory Measures
Prazo: Baseline and 12 weeks
|
Safety will be evaluated through changes in comprehensive metabolic panel laboratory measurements, including renal function, liver function, and electrolyte measurements. Laboratory results will be assessed at baseline and after 12 weeks of supplementation and summarized by treatment group. |
Baseline and 12 weeks
|
|
Supplement Adherence
Prazo: Throughout the 12-week intervention
|
Adherence to daily Panthea Core or placebo supplementation will be monitored throughout the intervention using participant-reported information collected through biweekly REDCap questionnaires. Adherence will be summarized descriptively, with a protocol target of at least 80%. |
Throughout the 12-week intervention
|
|
Study Retention
Prazo: From enrollment through completion of the 12-week intervention
|
Study retention will be assessed as the proportion of enrolled participants who complete the planned intervention and post-intervention assessments. The protocol specifies a retention target of at least 75%. |
From enrollment through completion of the 12-week intervention
|
Medidas de resultados secundários
Medidas de resultados secundários
Medida de resultado |
Descrição da medida |
Prazo |
|---|---|---|
|
Change in Flow-Mediated Dilation (FMD)
Prazo: Baseline to 12 weeks
|
Endothelial function will be assessed using brachial artery ultrasound flow-mediated dilation, expressed as percentage change in vessel diameter following temporary forearm occlusion. |
Baseline to 12 weeks
|
|
Change in Heart Rate Variability (HRV)
Prazo: Baseline to 12 weeks
|
Cardiovagal modulation will be evaluated using time-domain and frequency-domain measures derived from electrocardiogram recordings. |
Baseline to 12 weeks
|
|
Change in Cardiovagal Baroreflex Sensitivity
Prazo: Baseline to 12 weeks
|
Cardiovagal baroreflex sensitivity will be assessed using changes in ECG R-R intervals relative to changes in systolic blood pressure, expressed in ms/mmHg. |
Baseline to 12 weeks
|
|
Change in Sympathetic Baroreflex Sensitivity
Prazo: Baseline to 12 weeks
|
Sympathetic baroreflex sensitivity will be evaluated using changes in MSNA relative to diastolic blood pressure, expressed in bursts/100 heartbeats/mmHg as described in the protocol. |
Baseline to 12 weeks
|
|
Change in Blood Pressure
Prazo: Baseline to 12 weeks
|
Systolic and diastolic blood pressure will be measured at baseline and after the 12-week intervention to assess changes in blood pressure as a physiological parameter. |
Baseline to 12 weeks
|
|
Change in Menopause-Specific Quality of Life
Prazo: Baseline to 12 weeks
|
Menopausal symptoms and quality of life will be assessed using the Menopause-Specific Quality of Life (MENQOL) questionnaire, including vasomotor, physical, psychosocial, and sexual domains. |
Baseline to 12 weeks
|
|
Change in Depressive Symptoms (PHQ-9)
Prazo: Baseline to 12 weeks
|
Depressive symptoms will be evaluated using the nine-item Patient Health Questionnaire (PHQ-9). |
Baseline to 12 weeks
|
|
Change in Insomnia Severity (ISI)
Prazo: Baseline to 12 weeks
|
Insomnia symptoms will be assessed using the seven-item Insomnia Severity Index. |
Baseline to 12 weeks
|
|
Change in Subjective Sleep Quality (PSQI)
Prazo: Baseline to 12 weeks
|
(PSQI) Subjective sleep quality and disturbances will be assessed using the Pittsburgh Sleep Quality Index. |
Baseline to 12 weeks
|
|
Change in Objective Sleep Parameters
Prazo: Baseline to 12 weeks
|
Sleep will be measured using WatchPAT ONE-M monitoring before baseline and post-intervention physiological testing. |
Baseline to 12 weeks
|
|
Change in Cognitive Function (MoCA)
Prazo: Baseline to 12 weeks
|
Cognitive function will be evaluated using Montreal Cognitive Assessment scores before and after supplementation. |
Baseline to 12 weeks
|
|
Change in Gut Microbiome Composition
Prazo: Baseline to 12 weeks
|
Fecal microbiome sequencing will be used to evaluate changes in microbial composition and the abundance of Akkermansia muciniphila after supplementation. |
Baseline to 12 weeks
|
Colaboradores e Investigadores
Patrocinador
Patrocinador
Investigadores
Investigadores
- Investigador principal: Manda Keller-Ross, University of Minnesota
Datas de registro do estudo
Datas Principais do Estudo
Início do estudo (Estimado)
Início do estudo
Conclusão Primária (Estimado)
Conclusão Primária
Conclusão do estudo (Estimado)
Conclusão do estudo
Datas de inscrição no estudo
Enviado pela primeira vez
Enviado pela primeira vez
Enviado pela primeira vez que atendeu aos critérios de CQ
Enviado pela primeira vez que atendeu aos critérios de CQ
Primeira postagem (Real)
Primeira postagem
Atualizações de registro de estudo
Última Atualização Postada (Real)
Última Atualização Postada
Última atualização enviada que atendeu aos critérios de controle de qualidade
Última atualização enviada que atendeu aos critérios de controle de qualidade
Última verificação
Última verificação
Mais Informações
Termos relacionados a este estudo
Palavras-chave
Termos MeSH relevantes adicionais
Outros números de identificação do estudo
Outros números de identificação do estudo
- PT-2026-34798
Informações sobre medicamentos e dispositivos, documentos de estudo
Estuda um medicamento regulamentado pela FDA dos EUA
Estuda um produto de dispositivo regulamentado pela FDA dos EUA
Essas informações foram obtidas diretamente do site clinicaltrials.gov sem nenhuma alteração. Se você tiver alguma solicitação para alterar, remover ou atualizar os detalhes do seu estudo, entre em contato com register@clinicaltrials.gov. Assim que uma alteração for implementada em clinicaltrials.gov, ela também será atualizada automaticamente em nosso site .